Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease

Australas J Dermatol. 2023 Nov;64(4):e376-e378. doi: 10.1111/ajd.14154. Epub 2023 Sep 12.
No abstract available

Keywords: Charcot-Marie-Tooth; demyelinating neurological disorders; interleukin (IL)-23; psoriasis; risankizumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal
  • Charcot-Marie-Tooth Disease* / complications
  • Charcot-Marie-Tooth Disease* / drug therapy
  • Humans
  • Psoriasis* / complications
  • Psoriasis* / drug therapy

Substances

  • risankizumab
  • Antibodies, Monoclonal